Woodcliff Lake, NJ, Jan. 18, 2013 - Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for lamotrigine 25 mg, 50 mg, 100 mg, 200 mg, 250 mg and 300 mg extended-release (ER) tablets. Lamotrigine ER is the generic version of GlaxoSmithKline's Lamictal® XR and is indicated as adjunctive therapy for partial onset seizures with or without secondary generalization in patients
End-of-day quote
Other stock markets
|
||
- USD | - |
|
1st Jan change | Capi. | |
---|---|---|
+17.53% | 43.26B | |
+17.04% | 21.6B | |
+21.10% | 15.93B | |
+24.54% | 15.1B | |
+55.27% | 12.95B | |
-0.05% | 6.79B | |
-16.28% | 6.29B | |
+19.77% | 6.04B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- Stock
- News Par Pharmaceutical Companies, Inc.
- Par Pharmaceutical Companies, Inc. : Par Pharmaceutical Begins Shipment of Generic Lamictal® XR